HKSTP currently describes support of up to HK$6 million, comprising financial subsidy and an upfront grant earmarked for regulatory activities such as clinical trials. The programme is materially different from a general software incubator: laboratory access, translational evidence, regulatory planning and a four-year milestone plan are central.
Map the evidence chain before the funding chain
A biomedical plan should connect the intended use, scientific claim, validation work, quality controls and regulatory route. The next experiment should reduce a named risk; it should not exist only because a funding category can pay for it.
Set milestones around evidence that another party can inspect: assay performance, reproducibility, safety data, prototype verification, regulatory submission readiness or a properly defined clinical endpoint.
Budget for facilities and regulatory work separately
HKSTP highlights access to biomedical core facilities, laboratories, industry partners and regulatory support. Build a realistic schedule for facility booking, specialist staff, consumables, external testing and quality documentation; these are often the real constraints.
Treat the maximum as a package, not cash in the bank
The current programme page describes up to HK$4 million financial subsidy plus an upfront grant of up to HK$2 million for regulatory activities such as clinical trials. Applicants should verify milestone, eligible-cost and disbursement conditions in the latest guide before using those figures in a runway forecast.
Primary sources
These links are published by the programme operator or responsible authority. Recheck them immediately before applying.
Reviewed by the HK Grant Resource editorial desk on 4 August 2026 against the primary sources above.
Read our verification method →